$0.24
(Market cap
$30 Mln
Revenue (TTM)
$0 Mln
P/E Ratio
--
P/B Ratio
4.1
Div. Yield
0 %
Quality Score
/10
Growth Score
/10
Valuation Score
/10
Momentum Score
/10
Stock Range
Today’s Range
52 Week Range
Liquidity
Fundamentals
-
Net Profit (TTM)
$-- Mln
-
ROE
-20.6 %
-
ROCE
-- %
-
Industry P/E
--
-
EV/EBITDA
-1.6
-
Debt to Equity
0
-
Book Value
$--
-
EPS
$-8.8
-
Face value
--
-
Shares outstanding
5,829,223
10 Years Aggregate
CFO
$-105.58 Mln
EBITDA
$-143.95 Mln
Net Profit
$-165.32 Mln
Performance
|
Company
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|---|---|---|---|---|---|---|---|
|
Quantum BioPharma
| -2.6 | 135.4 | 95.3 | -13.5 | -53.5 | -42.1 | -- |
|
BSE Sensex
| -11.1 | -2.1 | -8.9 | -7.5 | 6.6 | 9.1 | 11.4 |
|
S&P Small-Cap 600#
| -5.8 | -5.3 | -13.7 | -6.3 | 5.3 | 3.0 | 5.5 |
|
Company
|
2025
|
2023
|
2022
|
2021
|
2020
|
2019
|
|---|---|---|---|---|---|---|
|
Quantum BioPharma
| 98.4 | 16.7 | -22.7 | -34.6 | -71.3 | -87.4 |
|
S&P Small-Cap 600
| 4.0 | 13.9 | -17.4 | 25.3 | 9.6 | 20.9 |
|
BSE Sensex
| 9.1 | 18.7 | 4.4 | 22.0 | 15.8 | 14.4 |
Essential Checks
View DetailsIs there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
Financials
View DetailsKey Ratios
View Details
5Y Avg -- 3Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Peers
View DetailsCompany |
Price ($) | Market Cap ($ Mln) | Revenue (TTM) | Net Profit (TTM) | OPM (%) | ROE (%) | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
|
Quantum BioPharma
|
7.1 | 29.9 | 0.0 | -26.2 | -- | -284.6 | -- | 4.1 |
|
Quantum BioPharma
|
7.1 | 29.9 | 0.0 | -31.0 | -- | -656.3 | -- | 4.1 |
| 5.3 | 2,005.6 | 10,552.2 | -1,189.5 | 22.9 | -- | -- | 18.8 | |
| 1.4 | 372.2 | 937.4 | -11.0 | -0.7 | -1 | -- | 0.5 |
Shareholding Pattern
View DetailsAbout Quantum BioPharma
Quantum BioPharma Ltd., together with its subsidiaries, operates as a biopharmaceutical company. The company operates through two segments, Biopharmaceutical Innovation and Strategic Investments. It researches and develops a portfolio of assets and... biotech solutions for the treatment of neurodegenerative, inflammatory and metabolic disorders, and alcohol misuse disorders with drug candidates in different stages of development. The company's lead compound is Lucid-MS, a patented new chemical entity that is in Phase 2 clinical trial to prevent and reverse myelin degradation, the underlying mechanism of multiple sclerosis, in preclinical models. It also develops FSD-PEA, which is in preparation for Phase 2 trial for the treatment of inflammatory diseases, such as mast cell activation syndrome; Lucid-PSYCH to treat major depressive disorder; and unbuzzd, a dietary supplement for the treatment of alcohol misuse. In addition, the company maintains a portfolio of strategic investments comprising loans secured by residential property. The company was formerly known as FSD Pharma Inc. and changed its name to Quantum BioPharma Ltd., in August 2024. Quantum BioPharma Ltd. was founded in 1998 and is based in Toronto, Canada. Address: 1 Adelaide Street East, Toronto, ON, Canada, M5C 2V9 Read more
-
Founder, CEO, President & Executive Co-Chairman
Mr. Zeeshan Saeed
-
Founder, CEO, President & Executive Co-Chairman
Mr. Zeeshan Saeed
-
Headquarters
--
-
Website
--
Value Research Ratings
Our rating system has guided millions of investors in the past 20 years.
FAQs for Quantum BioPharma
What is the current share price of Quantum BioPharma Ltd Today?
The share price of Quantum BioPharma Ltd is $7.11 (NASDAQ) as of 15-May-2026 10:39 EDT. Quantum BioPharma Ltd has given a return of -53.53% in the last 3 years.
What is the current PB & PE ratio of Quantum BioPharma Ltd?
Since, TTM earnings of Quantum BioPharma Ltd is negative, P/E ratio is not available.
The P/B ratio of Quantum BioPharma Ltd is 4.13 times as on , a 63 discount to its peers’ median range of 11.16 times.
PE & PB ratio at the end of financial year.
| Year | P/E Ratio | P/B Ratio |
|---|---|---|
|
2025
|
-0.84
|
3.17
|
|
2024
|
-0.26
|
0.32
|
|
2023
|
-3.34
|
4.52
|
|
2022
|
-2.17
|
1.68
|
|
2021
|
-1.88
|
1.22
|
What is the 52 Week High and Low of Quantum BioPharma Ltd?
The 52-week high and low of Quantum BioPharma Ltd are Rs -- and Rs -- as of 15-May-2026.
Should I invest in Quantum BioPharma Ltd?
Before investing in Quantum BioPharma Ltd, assess your goals, risk tolerance, and if the company aligns with your long-term plan. Carefully review its business model, financials, and valuation. Avoid making decisions based on tips or short-term trends.
New Process Alert 
Seems like you've uploaded a wrong QR code. Please upload the QR code downloaded from MF Central platform.